Luna FRA, Cortés PEC

Language: Spanish
References: 20
Page: 717-723
PDF size: 559.40 Kb.

ABSTRACT

Background: Confluent and reticulated papillomatosis of Gougerot-Carteaud is a rare dermatosis that mainly affects adolescents and young adults, characterized by hyperpigmented papules that coalesce to form plaques. Currently, treatment continues to be nonspecific, but good results have been seen with systemic antibiotics in conjunction with a combination of topical drugs.
Clinic cases: This paper reports the case of two male patients with confluent and reticulated papillomatosis who presented a chronic dermatosis composed of hyperpigmented plaques on the neck, trunk, and upper back. Both patients were successfully treated by combining minocycline together with a topical keratolytic and retinoid. Meanwhile in one patient weight control therapy was added.
Conclusions: This dermatosis is a rare and little-recognized entity. Its repercussions on physical appearance and mental state are irrefutable, therefore it is important to recognize it in time and treat it appropriately. To date, the first line treatment consists of minocycline; it is recommended to use a combined treatment to improve the results and avoid relapses, adding in patients with metabolic disorders a multidisciplinary management of weight control and insulin levels to favor remission.

REFERENCES

1. Arteaga R, Fernández RF, Arenas R, Papilomatosis confluentey reticulada de Gougerot y Carteaud: correlaciónmicológica e histopatológica de 5 casos. Dermatol CMQ 2013; 11 (2): 84-88.

2. Rodríguez-Carreón AA, Arenas-Guzmán R, Fonte-Ávalos V,et al. Papilomatosis reticulada y confluente de Gougerot-Carteaud. Un caso con excelente respuesta a minociclina.Gac Méd Méx 2008; 144 (1): 67-70.

3. Lim JHL, Tey HL, Chong WS. Confluent and reticulatedpapillomatosis: diagnostic and treatment challenges. ClinCosmet Invest Dermatol 2016; 9: 217-223. doi:10.2147/CCID.S92051

4. Le C. Bedocs PM. Confluent and reticulated papillomatosis.Treasure Island (FL): StatPearls Publishing 2022.

5. Bernués-Bergua T, Monte-Serrano J, Prieto-Torres L. Papilomatosisreticulada y confluente de Gougerot y Carteaud.Un reto diagnóstico y terapéutico. Semergen 2021; 47 (6):43-44. doi: 10.1016/j.semerg.2021.03.012

6. Arenas R. Papilomatosis confluente y reticulada. En: ArenasR. Dermatología atlas, diagnóstico y tratamiento. Ciudadde México: McGraw Hill, 2019: 946-949.

7. Herz M, Pandya A. Papilomatosis confluente y reticuladade Gougerot y Carteaud. Revisión del tema y reporte deun caso. Dermatol CMQ 2006; 4 (4): 292-294.

8. Cabanillas M, Monteagudo B, León E, De las Heras C,Cacharrón JM. Papilomatosis reticulada y confluente deGougerot-Carteaud. An Pediatr 2008; 68 (6): 628-629. doi:10.1157/13123302

9. James WD, Elston DM, McMahon PJ. Pityriasis rosea,pityriasis rubra pilaris, and other papulosquamous andhyperkeratotic diseases. In: Andrews’ Diseases of the Skin:Clinical Atlas. Philadelphia: Elsevier; 2018: 139-151.

10. Carrillo R, Carrillo LD, Carrillo JR. Papilomatosis reticuladay confluente de Gougerot-Carteaud. Reporte deun caso y revisión bibliográfica. Med Int Méx 2008; 24(4): 313-318.

11. Davis MDP, Weenig RH y Camilleri MJ, Confluent andreticulate papillomatosis (Gougerot-Carteaud syndrome):a minocycline-responsive dermatosis without evidencefor yeast in pathogenesis. A study of 39 patients and aproposal of diagnostic criteria: Confluent and reticulatepapillomatosis, Br J Dermatol 2006; 154 (2): 287-293.doi:10.1111/j.1365-2133.2005.06955.x

12. Mufti A, Sachdeva M, Maliyar K, Langsang RP, et al. Treatmentoutcomes in confluent and reticulated papillomatosis:A systematic review. J Am Acad Dermatol 2021; 84 (3):825-829. doi:10.1016/j.jaad.2020.08.133

13. Fagundo E, Martínez-Fernández M, Sánchez-SambucetyP, Rodríguez-Prieto MA. Papilomatosis confluente yreticulada de Gougerot-Carteaud: respuesta al trata-miento con minociclina. Actas Dermo-Sifiliogr 2004;95 (6): 394-396.

14. Heymann WR. Confluent and reticulated papillomatosis,prurigo pigmentosa, and antibiotic preference. J Am AcadDermatol 2023; 89: 233-4. doi:10.1016/j.jaad.2023.05.066

15. American Osteopathic College of Dermatology. Minocycline.Missouri: American Osteopathic College ofDermatology.

16. Smith K, Leyden JJ. Safety of doxycycline and minocycline:a systematic review. Clin Ther 2005; 27 (9): 1329-1342.doi:10.1016/j.clinthera.2005.09.005

17. Kuo AM, Kamat S, D’Ovidio TJ, Zhou RZ, et al. Associationof confluent and reticulated papillomatosis with obesityand resolution after treatment with doxycycline: A retrospectivecohort study. J Am Acad Dermatol 2023; 89 (2):348-350. doi:10.1016/j.jaad.2023.01.050

18. Bernardes Filho F, Quaresma MV, Rezende FC, Kac BK, etal. Confluent and reticulate papillomatosis of Gougerot-Carteaud and obesity: dermoscopic findings. An BrasDermatol 2014; 89 (3): 507-509. doi:10.1590/abd1806-4841.20142705

19. Cannavò SP, Guarneri C, Borgia F, Guarneri B. Confluentand reticulated papillomatosis and acanthosis nigricansin an obese girl: two distinct pathologies with a commonpathogenetic pathway or a unique entity dependent oninsulin resistance? J Eur Acad Dermatol Venereol 2006;

20. 20 (4): 478-480. doi:10.1111/j.1468-3083.2006.01476.x20. Lahouel M, Aounallah A, Mokni S, Belajouza C, DenguezliM. Confluent and reticulated papillomatosis associatedwith obesity: Case series of three patients successfullytreated with oral doxycycline. Dermatol Pract Concept2021; 11 (2): e2021006. doi:10.5826/dpc.1102a06